{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T11:03:31Z","timestamp":1790334211521,"version":"4.1.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.dmd.2026.100358","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T14:50:54Z","timestamp":1783090254000},"page":"100358","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Breaking the 1% unbound threshold: an IQ consortium whitepaper on the evaluation of plasma protein binding of highly bound compounds"],"prefix":"10.1016","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7818-5488","authenticated-orcid":false,"given":"Faraz","family":"Kazmi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8309-9315","authenticated-orcid":false,"given":"Ulrike","family":"Gradhand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5243-2524","authenticated-orcid":false,"given":"Eric T.","family":"Gangl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1900-9331","authenticated-orcid":false,"given":"Robert","family":"Fricke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0172-6108","authenticated-orcid":false,"given":"Tanya","family":"Aldinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Chambers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Donzelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6183-387X","authenticated-orcid":false,"given":"Bernard G.","family":"Francq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8864-2183","authenticated-orcid":false,"given":"Paul J.","family":"Harradine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9mi","family":"Kazma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5635-8446","authenticated-orcid":false,"given":"Saro","family":"Mardirosian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marie","family":"Nicolas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2120-5734","authenticated-orcid":false,"given":"Raku","family":"Shinkyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sinz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0291-6134","authenticated-orcid":false,"given":"Patricia","family":"Stuart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanaka","family":"Tatikola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias Beat","family":"Wittwer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0718-2260","authenticated-orcid":false,"given":"Gloria","family":"Vendrell-Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengyin","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4414-2804","authenticated-orcid":false,"given":"John C.","family":"Kalvass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.dmd.2026.100358_bib1","doi-asserted-by":"crossref","first-page":"170","DOI":"10.2174\/138620710790596745","article-title":"Plasma protein binding in drug discovery and development","volume":"13","author":"Howard","year":"2010","journal-title":"Comb Chem High Throughput Screen"},{"issue":"4","key":"10.1016\/j.dmd.2026.100358_bib2","doi-asserted-by":"crossref","first-page":"450","DOI":"10.2174\/156802611794480918","article-title":"Do we need to optimize plasma protein and tissue binding in drug discovery?","volume":"11","author":"Liu","year":"2011","journal-title":"Curr Top Med Chem"},{"issue":"12","key":"10.1016\/j.dmd.2026.100358_bib3","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/nrd3287","article-title":"The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery","volume":"9","author":"Smith","year":"2010","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"10.1016\/j.dmd.2026.100358_bib4","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1007\/s11095-007-9502-2","article-title":"On the rate and extent of drug delivery to the brain","volume":"25","author":"Hammarlund-Udenaes","year":"2008","journal-title":"Pharm Res"},{"issue":"7","key":"10.1016\/j.dmd.2026.100358_bib5","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1021\/acs.molpharmaceut.3c00208","article-title":"Estimating unbound drug concentrations in simulated human lung fluid: relevance to lung antibiotic PKPD","volume":"20","author":"Keemink","year":"2023","journal-title":"Mol Pharm"},{"issue":"12","key":"10.1016\/j.dmd.2026.100358_bib6","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.1016\/j.xphs.2017.09.005","article-title":"Industry perspective on contemporary protein-binding methodologies: considerations for regulatory drug-drug interaction and related guidelines on highly bound drugs","volume":"106","author":"Di","year":"2017","journal-title":"J Pharm Sci"},{"issue":"24","key":"10.1016\/j.dmd.2026.100358_bib7","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.4155\/bio.13.274","article-title":"The bioanalytical challenge of determining unbound concentration and protein binding for drugs","volume":"5","author":"Nilsson","year":"2013","journal-title":"Bioanalysis"},{"issue":"7","key":"10.1016\/j.dmd.2026.100358_bib8","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1002\/jps.2600730738","article-title":"Plasma protein binding of warfarin: methodological considerations","volume":"73","author":"Mungall","year":"1984","journal-title":"J Pharm Sci"},{"issue":"3","key":"10.1016\/j.dmd.2026.100358_bib9","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1002\/jps.23013","article-title":"Impact of recovery on fraction unbound using equilibrium dialysis","volume":"101","author":"Di","year":"2012","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.dmd.2026.100358_bib10","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ejps.2018.07.004","article-title":"Concentration-dependent plasma protein binding: expect the unexpected","volume":"122","author":"Nation","year":"2018","journal-title":"Eur J Pharm Sci"},{"issue":"2","key":"10.1016\/j.dmd.2026.100358_bib11","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/jps.20777","volume":"96","author":"Berezhkovskiy","year":"2007","journal-title":"J Pharm Sci"},{"issue":"7","key":"10.1016\/j.dmd.2026.100358_bib12","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1016\/j.xphs.2018.03.023","article-title":"Nonlinear protein binding: not what you think","volume":"107","author":"Deitchman","year":"2018","journal-title":"J Pharm Sci"},{"issue":"11","key":"10.1016\/j.dmd.2026.100358_bib13","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1016\/j.xphs.2023.06.015","article-title":"Prediction of the time to reach equilibrium for improved estimation of the unbound fraction of compounds in equilibrium dialysis using kinetic modeling","volume":"112","author":"Bae","year":"2023","journal-title":"J Pharm Sci"},{"issue":"8","key":"10.1016\/j.dmd.2026.100358_bib14","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1002\/jps.24506","article-title":"Plasma protein binding of challenging compounds","volume":"104","author":"Riccardi","year":"2015","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.dmd.2026.100358_bib15","series-title":"Guideline on the investigation of drug interactions. Vol. CPMP\/EWP\/560\/95\/Rev. 1 Corr. 2","year":"2013"},{"key":"10.1016\/j.dmd.2026.100358_bib16","series-title":"In Vitro Metabolism- and Transporter-Mediated Drug-Drug Interaction Studies \u2013 Guidance for Industry","first-page":"43","year":"2020"},{"key":"10.1016\/j.dmd.2026.100358_bib17","series-title":"Guideline on Drug Interactions for Drug Development and Information Provision","year":"2018"},{"issue":"4","key":"10.1016\/j.dmd.2026.100358_bib18","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1124\/dmd.117.078915","article-title":"Mathematical and experimental validation of flux dialysis method: an improved approach to measure unbound fraction for compounds with high protein binding and other challenging properties","volume":"46","author":"Kalvass","year":"2018","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2026.100358_bib19","unstructured":"Kazmi F, Buckley DB, Yerino P, Ogilvie BW, Parkinson A. Effects of plasma on cytochrome P450 (CYP) inhibition studies in human liver microsomes (HLM): consequence on in vitro-in vivo extrapolations (IVIVE). Presented at: ISSX 16th; 2009; Baltimore, MD. Abstract 192. Drug Metab Rev., 41 (supplement 3)."},{"issue":"9","key":"10.1016\/j.dmd.2026.100358_bib20","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1002\/jps.23614","article-title":"Plasma protein binding: from discovery to development","volume":"102","author":"Bohnert","year":"2013","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.dmd.2026.100358_bib21","series-title":"Drug Interaction Studies M12 Vol","first-page":"68","year":"2024"},{"issue":"8","key":"10.1016\/j.dmd.2026.100358_bib22","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/bdd.325","article-title":"Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery","volume":"23","author":"Kalvass","year":"2002","journal-title":"Biopharm Drug Dispos"},{"issue":"3","key":"10.1016\/j.dmd.2026.100358_bib23","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1021\/mp800004s","article-title":"Impact of pH on plasma protein binding in equilibrium dialysis","volume":"5","author":"Kochansky","year":"2008","journal-title":"Mol Pharm"},{"issue":"3","key":"10.1016\/j.dmd.2026.100358_bib24","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/j.xphs.2020.11.018","article-title":"A novel method for preventing non-specific binding in equilibrium dialysis assays using Solutol(R) as an additive","volume":"110","author":"Srivastava","year":"2021","journal-title":"J Pharm Sci"},{"issue":"3","key":"10.1016\/j.dmd.2026.100358_bib25","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.xphs.2018.10.011","article-title":"Improving confidence in the determination of free fraction for highly bound drugs using bidirectional equilibrium dialysis","volume":"108","author":"Chen","year":"2019","journal-title":"J Pharm Sci"},{"issue":"11","key":"10.1016\/j.dmd.2026.100358_bib26","doi-asserted-by":"crossref","first-page":"3745","DOI":"10.1016\/j.xphs.2019.08.004","article-title":"Applying two orthogonal methods to assess accuracy of plasma protein binding measurements for highly bound compounds","volume":"108","author":"Ryu","year":"2019","journal-title":"J Pharm Sci"},{"issue":"10","key":"10.1016\/j.dmd.2026.100358_bib27","doi-asserted-by":"crossref","first-page":"4586","DOI":"10.1002\/jps.21317","article-title":"Validation of a rapid equilibrium dialysis approach for the measurement of plasma protein binding","volume":"97","author":"Waters","year":"2008","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.dmd.2026.100358_bib28","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/978-1-0716-1554-6_5","article-title":"Consideration of the unbound drug concentration in enzyme kinetics","volume":"2342","author":"Waters","year":"2021","journal-title":"Methods Mol Biol"},{"issue":"6","key":"10.1016\/j.dmd.2026.100358_bib29","doi-asserted-by":"crossref","first-page":"405","DOI":"10.2165\/00003088-199835060-00001","article-title":"Clinical pharmacokinetics of mibefradil","volume":"35","author":"Welker","year":"1998","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"10.1016\/j.dmd.2026.100358_bib30","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1468-1293.2006.00356.x","article-title":"Characterization of nelfinavir binding to plasma proteins and the lack of drug displacement interactions","volume":"7","author":"Motoya","year":"2006","journal-title":"HIV Med"},{"key":"10.1016\/j.dmd.2026.100358_bib31","series-title":"NDA Approval Package for Viracept (nelfinavir), application No. 020779","year":"1997"},{"issue":"4","key":"10.1016\/j.dmd.2026.100358_bib32","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/00007691-198712000-00011","article-title":"Total plasma concentrations, red blood cell concentrations, and radioreceptor assay values compared with unbound plasma concentrations of thioridazine and thioridazine metabolites in psychiatric patients","volume":"9","author":"Nyberg","year":"1987","journal-title":"Ther Drug Monit"},{"issue":"4","key":"10.1016\/j.dmd.2026.100358_bib33","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1177\/0091270005274549","article-title":"Review of UCN-01 development: a lesson in the importance of clinical pharmacology","volume":"45","author":"Fuse","year":"2005","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.dmd.2026.100358_bib34","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/BF00495864","article-title":"Binding of thioridazine and thioridazine metabolites to serum proteins. An in vitro study","volume":"319","author":"Nyberg","year":"1982","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"1","key":"10.1016\/j.dmd.2026.100358_bib35","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1208\/s12248-024-00988-6","article-title":"Interference of plasticizers on plasma protein binding measurements","volume":"27","author":"Harrison","year":"2024","journal-title":"AAPS J"},{"issue":"3","key":"10.1016\/j.dmd.2026.100358_bib36","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1124\/dmd.110.036988","article-title":"Control and measurement of plasma pH in equilibrium dialysis: influence on drug plasma protein binding","volume":"39","author":"Curran","year":"2011","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.dmd.2026.100358_bib37","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1208\/s12248-024-00987-7","article-title":"Prediction of drug-drug interactions for highly plasma protein bound compounds","volume":"27","author":"Tess","year":"2024","journal-title":"AAPS J"},{"issue":"3","key":"10.1016\/j.dmd.2026.100358_bib38","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/j.1365-2125.2006.02764.x","article-title":"Effect of multiple doses of montelukast on the pharmacokinetics of rosiglitazone, a CYP2C8 substrate, in humans","volume":"63","author":"Kim","year":"2007","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"10.1016\/j.dmd.2026.100358_bib39","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s00228-006-0136-9","article-title":"Montelukast and zafirlukast do not affect the pharmacokinetics of the CYP2C8 substrate pioglitazone","volume":"62","author":"Jaakkola","year":"2006","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.dmd.2026.100358_bib40","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.clpt.2005.11.002","article-title":"Telithromycin, but not montelukast, increases the plasma concentrations and effects of the cytochrome P450 3A4 and 2C8 substrate repaglinide","volume":"79","author":"Kajosaari","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmd.2026.100358_bib41","volume":"4","year":"2022"},{"issue":"8","key":"10.1016\/j.dmd.2026.100358_bib42","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1021\/acs.analchem.2c04864","article-title":"New methodology for determining plasma protein binding kinetics using an enzyme reporter assay coupling with high-resolution mass spectrometry","volume":"95","author":"Yan","year":"2023","journal-title":"Anal Chem"},{"issue":"8","key":"10.1016\/j.dmd.2026.100358_bib43","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1124\/dmd.123.001326","article-title":"Assumptions underlying hepatic clearance models: recognizing the influence of saturable protein binding on driving force concentration and discrimination between models of hepatic clearance","volume":"51","author":"Schulz Pauly","year":"2023","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"10.1016\/j.dmd.2026.100358_bib44","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1124\/dmd.122.001154","article-title":"Industry perspective on the pharmacokinetic and absorption, distribution, metabolism, and excretion characterization of heterobifunctional protein degraders","volume":"51","author":"Volak","year":"2023","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"10.1016\/j.dmd.2026.100358_bib45","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.xphs.2018.10.018","article-title":"Determination of the plasma protein binding of liraglutide using the EScalate(\u2217) equilibrium shift assay","volume":"108","author":"Ungewiss","year":"2019","journal-title":"J Pharm Sci"},{"issue":"5","key":"10.1016\/j.dmd.2026.100358_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmd.2025.100066","article-title":"Applications of contemporary tools to measure plasma protein binding of targeted protein degraders","volume":"53","author":"Niosi","year":"2025","journal-title":"Drug Metab Dispos"},{"issue":"11","key":"10.1016\/j.dmd.2026.100358_bib47","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1124\/dmd.123.001437","article-title":"Metabolism and excretion of therapeutic peptides: current industry practices, perspectives, and recommendations","volume":"51","author":"He","year":"2023","journal-title":"Drug Metab Dispos"},{"issue":"11","key":"10.1016\/j.dmd.2026.100358_bib48","doi-asserted-by":"crossref","first-page":"6020","DOI":"10.1093\/nar\/gkac456","article-title":"Considerations and recommendations for assessment of plasma protein binding and drug-drug interactions for siRNA therapeutics","volume":"50","author":"Humphreys","year":"2022","journal-title":"Nucleic Acids Res"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626006276?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626006276?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T10:15:53Z","timestamp":1790331353000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955626006276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":48,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0090955626006276"],"URL":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100358","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Breaking the 1% unbound threshold: an IQ consortium whitepaper on the evaluation of plasma protein binding of highly bound compounds","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100358","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100358"}}